CERO THERAPEUTICS HOLDINGS, INC.

CEROdata completeness 50%3 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'capex'; no data for concept 'totalDebt'; no data for concept 'interestExpense'

i. The business — what you’d actually own

Figure	FY 2022	FY 2023	FY 2025
Revenue	—	—	—
Net income	−$667,736¹	−$7.29M²	−$19.9M³
Operating cash flow	−$1.09M⁴	−$1.52M⁴	−$16.1M⁵
Capital expenditure	—	—	—
Free cash flow (derived)	—	—	—
Total debt	—	—	—
Cash & equivalents	$475,870⁶	$96,873⁶	$1.66M⁷
Diluted shares	—	5,838	—

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

iii. Is this a good business?

Moat signal · return on equity

— avg · 3y

Not enough data in the filings for a return-on-capital reading.

Management signal · capital allocation

−0% shares · 3y

Share count is roughly flat over 3 years — little dilution, little buyback.

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts